1.High frequency of cagA and vacA s1a/m2 Genotype among Helicobacter pylori Infected Gastric Biopsies of Pakistani Children
Faisal Rasheed ; Tanvir Ahmad ; Muhammad Ali ; Salman Ali ; Safia Ahmed ; Rakhshanda Bilal
Malaysian Journal of Microbiology 2011;7(3):167-170
The vacuolating cytotoxin VacA and cytotoxin associated gene product CagA, encoded by vacA and cagA are major virulence determinants associated with pathogenesis of Helicobacter pylori. The presence and prevalence of two major H. pylori virulence associated genes among gastric biopsies of Pakistani children were investigated in the current study. Fifty one gastric biopsy specimens of children were analysed for 16S rRNA, vacA and cagA genes using PCR. The results showed that 21 (41.2%) biopsies were positive for H. pylori as determined by 16S rRNA PCR. In the 21 H. pylori positive gastric biopsies, 19 (90.5%) showed vacA s1a, 1 (4.75%) was vacA s1b and 1 (4.75%) was vacA s2 whereas, 5 (23.8%) were vacA m1 and 16 (76.2%) were vacA m2. None of the H. pylori positive biopsies carried vacA s1c subtype. The cagA gene was found in 13 (61.9%) of H. pylori infected biopsies and different vacA combinations were found with or without cagA gene. H. pylori was detected with high frequency of cagA while vacA s1a and vacA m2 regions with vacA s1a/m2 genotype were predominant in H. pylori infected gastric biopsies of children.
2.Developing a deeper insight into reproductive biomarkers.
Braira WAHID ; Hamid BASHIR ; Muhammad BILAL ; Khansa WAHID ; Aleena SUMRIN
Clinical and Experimental Reproductive Medicine 2017;44(4):159-170
The development of biomarkers of reproductive medicine is still in its infancy because many black boxes are still present in reproductive medicine. Novel approaches to human infertility diagnostics and treatment must be developed because reproductive medicine has lagged behind in the implementation of biomarkers in clinical medicine. Despite the dearth of the available literature, the current rapid pace of publications suggests that this gap will soon be filled therefore; this review is a précis of the research that has been done so far and will provide a basis for the development of biomarkers in reproductive medicine.
Biomarkers*
;
Clinical Medicine
;
Humans
;
Infertility
;
Reproduction
;
Reproductive Medicine
3.Combination Treatment With Proton Pump Inhibitor Plus Prokinetic for Gastroesophageal Reflux Disease
Muhammad Ali TARIQ ; Bilal AHMED
Journal of Neurogastroenterology and Motility 2022;28(1):164-164
no abstract available.
4.Predictors of response to antiviral therapy in patients with chronic hepatitis C from Pakistani population.
Hafsa AZIZ ; Muhammad Amin ATHAR ; Shahnaz MURTAZA ; Javaid IRFAN ; Yasir WAHEED ; Iram BILAL ; Abida RAZA
Chinese Medical Journal 2011;124(9):1333-1337
BACKGROUNDHepatitis C virus (HCV) constitutes a major public health issue around the world, especially in developing countries like Pakistan. In this study, we assessed outcome of interferon (INF) treatment in chronic hepatitis C patients categorized by gender, age, and viral load.
METHODSIn this study, 750 HCV positive patients with genotype 3 were selected, out of which 616 completed the entire treatment. Their personal history, pre-treatment HCV RNA and serum alanine transaminase (ALT) was quantified. Patients were treated with combination therapy of INF-α 2b three million units (thrice a week) plus ribavirin (1000 - 1200 mg per day) for 24 weeks. After 24 weeks their HCV RNA and serum ALT level was quantified.
RESULTSOut of the 616 patients, 391 (63.5%) responded to therapeutic regimen (INF-α 2b plus ribavirin). Among the responders, 27.1% were men and 36.4% were women. Best treatment response was observed in patients having low viral load < 8 × 10(5) IU/ml and age ≤ 40 years than patients having low viral load and age > 40 years (73.2% vs. 60.3%, P = 0.05).
CONCLUSIONSBetter response to IFN-α 2b plus ribavirin was observed in patients with lower viral RNA and younger age. It suggests that all patients considered for treatment should have quantification of serum HCV RNA level. The result can be used to counsel patients on the likelihood of response and may influence the patient's decision on treatment.
Adult ; Antiviral Agents ; therapeutic use ; Female ; Genotype ; Hepatitis C, Chronic ; drug therapy ; virology ; Humans ; Interferon-alpha ; therapeutic use ; Male ; Pakistan ; Polymerase Chain Reaction ; RNA, Viral ; genetics ; Ribavirin ; therapeutic use ; Treatment Outcome
6.Dengue fever treatment with Carica papaya leaves extracts.
Nisar AHMAD ; Hina FAZAL ; Muhammad AYAZ ; Bilal Haider ABBASI ; Ijaz MOHAMMAD ; Lubna FAZAL
Asian Pacific Journal of Tropical Biomedicine 2011;1(4):330-333
The main objective of the current study is to investigate the potential of Carica papaya leaves extracts against Dengue fever in 45 year old patient bitten by carrier mosquitoes. For the treatment of Dengue fever the extract was prepared in water. 25 mL of aqueous extract of C. papaya leaves was administered to patient infected with Dengue fever twice daily i.e. morning and evening for five consecutive days. Before the extract administration the blood samples from patient were analyzed. Platelets count (PLT), White Blood Cells (WBC) and Neutrophils (NEUT) decreased from 176×10(3)/µL, 8.10×10(3)/µL, 84.0% to 55×10(3)/µL, 3.7×10(3)/µL and 46.0%. Subsequently, the blood samples were rechecked after the administration of leaves extract. It was observed that the PLT count increased from 55×10(3)/µL to 168×10(3)/µL, WBC from 3.7×10(3)/µL to 7.7×10(3)/µL and NEUT from 46.0% to 78.3%. From the patient feelings and blood reports it showed that Carica papaya leaves aqueous extract exhibited potential activity against Dengue fever. Furthermore, the different parts of this valuable specie can be further used as a strong natural candidate against viral diseases.
Antiviral Agents
;
isolation & purification
;
therapeutic use
;
Carica
;
chemistry
;
Dengue
;
drug therapy
;
Humans
;
Leukocyte Count
;
Male
;
Middle Aged
;
Plant Extracts
;
isolation & purification
;
therapeutic use
;
Plant Leaves
;
chemistry
;
Platelet Count
;
Treatment Outcome